Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Provenge regulatory update

DNDN received a Special Protocol Assessment (SPA) from the FDA's Center for Biologics Research and Evaluation (CBER) for DNDN's ongoing

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE